Reuters: Global Markets: Israeli biopharm firm Kamada mulls U.S. share offering

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Israeli biopharm firm Kamada mulls U.S. share offering Dec 10th 2012, 10:53 TEL AVIV | Mon Dec 10, 2012 5:53am EST TEL AVIV (Reuters) - Kamada (KMDA.TA) is looking at the possibility of making a share offer in the United States, the Israeli biopharmaceutical company said on Monday. "As of the date of this notice no decision has been taken as to the basic conditions of a possible offering and there is no certainty it will take place," it said in a statement. Glassia, Kamada's intravenous treatment for the lung-damaging genetic disorder alpha-1 antitrypsin deficiency (AATD), is marketed by Baxter International (BAX.N) in the United States. An inhaled version of the drug is in advanced clinical development. Traded on the Tel Aviv Stock Exchange, Kamada has a market value of 1.03 billion shekels ($269 million). Its shares were down 2.9 percent at 34.83 shekels in early afternoon trading.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions